Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). (Q38408716)
Jump to navigation
Jump to search
scientific article published on 03 July 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). |
scientific article published on 03 July 2015 |
Statements
1 reference
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). (English)
1 reference
C Zhou
1 reference
Y L Wu
1 reference
G Chen
1 reference
J Feng
1 reference
X-Q Liu
1 reference
C Wang
1 reference
S Zhang
1 reference
J Wang
1 reference
S Zhou
1 reference
S Ren
1 reference
S Lu
1 reference
L Zhang
1 reference
C Hu
1 reference
C Hu
1 reference
Y Luo
1 reference
L Chen
1 reference
M Ye
1 reference
J Huang
1 reference
X Zhi
1 reference
Y Zhang
1 reference
Q Xiu
1 reference
J Ma
1 reference
L Zhang
1 reference
C You
1 reference
3 July 2015
1 reference
1 reference
26
1 reference
9
1 reference
1877-1883
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference